Wellnex Pro D

Nutritional Therapy for Diabetes Management







Nitta Gelatin Inc.



About us

- Established in 1975
- 4 Manufacturing Locations in India
- One of the leading Gelatin & Collagen Peptide Manufacturer in India
- WHO-GMP, FSSC22000, ISO9001, ISO14001
- EDQM, USFDA Inspected facilities
- Shareholding
 - Nitta Gelatin Inc, Japan 42.96%
 - Kerala State Ind. Dev. Corporation 31.52%
 - Public 25.52% (listed in Mumbai & Cochin stock exchanges)

Nitta Gelatin Inc., Japan

- Established in January 1918,
- Headquarter at Osaka, Japan
- Consolidated Sales \$ 1 Billion
- 17 group companies
- Manufacturing locations in Japan, India, Canada, China, USA, Vietnam
- 5th Largest Gelatin Manufacturer



Diabetes – A global concern...





Pre Diabetes





4

Why Diabetes to be controlled?





- Higher risk of developing life-threatening health
- Diabetes affect heart and blood vessels, eyes, kidneys and nerves.
- Healthy diet, regular physical activity, maintaining a normal body weight are some ways to prevent or delay the onset of type 2 diabetes







- Commonly used oral hypoglycemic medications are
 Biguanides | Sulfonylureas | Alpha-glucosidase
 inhibitors | Thiazolidinediones/Glitazones | DPP-4
 inhibitors (gliptins)
- Lack of safe intervention for IGT group
- Monontherapy does not yield desired result
- Increasing incidence of MODY
- Adverse reactions
- Highly individualized treatment needs





Wellnex Pro D

Advanced Nutritional Therapy for Diabetes Management







Wellnex Pro D

Control diabetes in a healthy way

- Safe preventive supplement for IGT group (pre diabetes)
- No side effects on long term use
- Improve overall wellness (support bone, joint, muscle and skin)



Mechanism of Action



- Type 2 diabetic patients typically have little or no incretin-mediated augmentation of insulin secretion.
- The natural peptide is rapidly degraded by the enzyme dipeptidyl peptidase IV (DPP IV)
- The specific peptides in Wellnex Pro-D
 inhibits the enzyme DPP IV
- Thus prevents the degradation of the incretin hormones (GLP 1, GIP)

Clinical Results







HbA1c



- Population: 84 patients
- Double blind, Randomised, Two Arm
- Standard Therapy Sitagliptin + Vildagliptins
- Dosage : 10g (40), 5g (22), 2.5g (22) dosage
- Duration : 12 weeks (3 months)
- CTRI-ICMR registered



Clinical Results

- ✓ Significant reduction in fasting blood glucose (FBS)
- ✓ Significant reduction in HbA1C
- ✓ Significant Improvement in Insulin sensitivity
- ✓ No adverse effect
- ✓ Synergic effect with regular medical therapy
- ✓ Improvement in Quality of Life

Improvement Level

FBSHbA1C

٠

: 100- 125 mg/dL : 5.7 - 6.4% : 25% reduction

Insulin Resistance : 25

Data Source : 10g and 5g study



Not improved Improved

Make a Healthy choice

Wellnex Pro D is a proven & safe nutritional intervention for diabetes management and improve overall quality of life

Category	Wellnex Pro D	Regular Diabetic Supplements
Origin	Protein	Carbohydrate/fibers
Mechanism of action	Augment Insulin secretion (by inhibiting DPP-IV)	Satiety effect/low GI
Safety	No adverse side effects	No adverse side effects
Source	Natural	Natural
Additional Benefits	 Improves Joint Flexibility and Mobility 	Nil
	 Improves Bone Mineral Density, 	
	 Support Lean Muscle Mass, 	
	 Improves Skin Properties 	
Calorie	Low	Low
Allergen	Lactose Free, Soy Free, Gluten Free	Lactose Free, Soy Free, Gluten Free
Clinical Evidence	Clinically Tested	Clinically Tested







- Estimated that Clinical Nutrition Market will register 7% CAGR to cross \$80 billion by 2024
- One of the major drivers is increasing prevalence of diabetes
- Pre Diabetic population have no solution for preventing the onset of diabetes
- Changing lifestyle demands nutritional intervention

Strengthen your diabetic product portfolio with Wellnex Pro D







LIVE LIFE HAPPILY EVER AFTER

14





- A Double Blind, Prospective, Randomised, Comparative, Active Controlled, Two Arm, Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Collagen Peptide as an Add-On Nutritional Therapy in the Management of Diabetes Mellitus (type II) in Adult Subjects. ICMR - CTRI Registration No. CTRI/2015/02/005518
- A Double Blind, prospective, randomiised, Four Arm Clinical Study To Evaluate, The Safety, Efficacy And Tolerability Of Two Doses Of Collagen Peptide Iin, Comparison With Resistant Dextrin As A Nutraceutical Therapy In The Management Of Diabetes Mellitus (Type Ii) In Adult Subjjects... Icmr - Ctri Registration No. Ctri/2017/05/008464
- Chia-Ling J *et al.*, The development of bioactive peptides from dietary proteins as dipetidyl peptidase IV inhibitor for the management of type 2 diabetes. Biomedicine 2015; 5(3):9-15
- Hatanaka T *et al.*, Inhibitory effect of collagen derived tripeptides on Dipeptidyl peptidase-IV activity. J Enzyme Inhib Med Chem 2014 ;1-6
- Iba Y *et al.*, Oral Administration of Collagen Hydrolysates Improves Glucose Tolerance in Normal Mice through GLP-1-Dependent and -Independent Mechanisms. 2016; Accepted manuscript.
- Li-Chan, E. C. Y., Hunag, S. L., Jao, C. L., Ho, K. P., & Hsu, K. C. Peptides derived from Atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. Journal of Agricultural and Food Chemistry. 60(4),973–978 (2012)
- Jin Y, Yan J, Yu Y and Qi Y. Screening and identification of DPP IV inhibitory peptides from deer skin hydrolysates by an integrated approach of LC-MS/MS and in silico analysis. J Functional Foods. 18, 344-357 (2015)
- Hatanaka T, Kawakami K, Uraji M. Inhibitory effect of collagen derived tripeptides on Dipeptidyl peptidase-IV activity. J Enzyme Inhib Med Chem. 26(6), 823-828 (2014)
- Green B D, Flatt P R, Bailey C J. Dipeptidyl peptidase IV (DPP IV) inhibitors: n newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res. 3, 159-165 (2006)
- Zhu C, Li G, Peng H, Zang F, Chen Y, Li Y. Treatment with marine collagen peptides modulates glucose and lipid metabolism in Chinese patients with type 2 diabetes mellitus. 35, 797-804 (2010)